Fed Circ. Urged To Undo PTAB's Gene-Editing Patent Ruling
Regeneron Pharmaceuticals Inc. and a group of scientists have urged the Federal Circuit to reverse the U.S. Patent Trial and Appeal Board's finding that the Broad Institute is entitled to patents...To view the full article, register now.
Already a subscriber? Click here to view full article